{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:35:00Z","timestamp":1760888100439},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1007\/s11926-004-0083-3","type":"journal-article","created":{"date-parts":[[2007,6,2]],"date-time":"2007-06-02T12:30:08Z","timestamp":1180787408000},"page":"49-58","source":"Crossref","is-referenced-by-count":14,"title":["The use of intermittent human parathyroid hormone as a treatment for osteoporosis"],"prefix":"10.1007","volume":"6","author":[{"given":"Chad","family":"Deal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"83_CR1","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"R Neer","year":"2001","unstructured":"Neer R, Arnaud C, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434\u20131441. This is a pivotal trial of rhPTH 1-34 that showed vertebral and nonvertebral fracture reduction in postmenopausal women at high risk for fracture.","journal-title":"N Engl J Med"},{"key":"83_CR2","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1210\/endo.138.11.5505","volume":"138","author":"H Dobnig","year":"1997","unstructured":"Dobnig H, Turner RT: The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997, 138:4607\u20134612.","journal-title":"Endocrinology"},{"key":"83_CR3","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/bmj.280.6228.1340","volume":"280","author":"J Reeve","year":"1980","unstructured":"Reeve J, Meunier P, Parsons JA, et al.: Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. BMJ 1980, 280:1340\u20131344.","journal-title":"BMJ"},{"key":"83_CR4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/bmj.301.6747.314","volume":"301","author":"J Reeve","year":"1990","unstructured":"Reeve J, Davies UM, Hesp R, et al.: Human parathyroid peptide treatment of osteoporosis substantially increases spinal trabecular bone. BMJ 1990, 301:314\u2013318.","journal-title":"BMJ"},{"key":"83_CR5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF01625448","volume":"1","author":"J Reeve","year":"1991","unstructured":"Reeve J, Bradbeer JN, Arlot M: hPTH (1-34) treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic, and histological responses. Osteoporos Int 1991, 1:162\u2013170.","journal-title":"Osteoporos Int"},{"key":"83_CR6","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.1007\/BF01621907","volume":"3","author":"M Neer","year":"1993","unstructured":"Neer M, Slovik DM, Daly N, et al.: Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol. Osteoporos Int 1993, 3(suppl):S204-S205.","journal-title":"Osteoporos Int"},{"key":"83_CR7","first-page":"S162","volume":"16","author":"R Lindsay","year":"2001","unstructured":"Lindsay R, Scheele WH, Clancy AD, et al.: Incident vertebral fractures during an 18 month observation period following discontinuation of LY 333334 (recombinant human parathyroid hormone (1-34), rhPTH (1-34)) use in postmenopausal women with osteoporosis. J Bone Miner Res 2001, 16(suppl):S162.","journal-title":"J Bone Miner Res"},{"key":"83_CR8","unstructured":"Scheele W: Paper presented the 84th Annual Meeting of the Endocrine Society. San Francisco, CA: June 19\u201322, 2002."},{"key":"83_CR9","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1359\/jbmr.2001.16.11.1962","volume":"16","author":"Orwoll","year":"2001","unstructured":"Orwoll, E, Scheele WH, Clancy AD, et al.: Recombinant human parathyroid hormone (1-34) therapy reduces moderate\/ severe vertebral fracture incidence in men with low bone density. J Bone Miner Res 2001, 16(suppl):S162. This is a trial of rhPTH 1-34 in men that demonstrates increases in BMD comparable with women and significant reduction in moderate (26% to 40% height reduction) and severe (>40%) in treated patients.","journal-title":"J Bone Miner Res"},{"key":"83_CR10","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1359\/jbmr.2000.15.1.175","volume":"15","author":"R Lindsay","year":"2000","unstructured":"Lindsay R, Hodsman A, Genant H: A randomized controlled multicenter study of 1-84 hPTH for treatment of postmenopausal osteoporosis. J Bone Miner Res 2000, 15(suppl):S175.","journal-title":"J Bone Miner Res"},{"key":"83_CR11","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"248","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, et al.: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 1996, 248:1535\u20131541.","journal-title":"Lancet"},{"key":"83_CR12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999, 282:637\u2013645.","journal-title":"JAMA"},{"key":"83_CR13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne H, Sorensen OH et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000, 11:83\u201391.","journal-title":"Osteoporos Int"},{"key":"83_CR14","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1144\u20131352.","journal-title":"JAMA"},{"key":"83_CR15","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","volume":"350","author":"J Lindsay R. Nieves","year":"1997","unstructured":"Lindsay R. Nieves J, Formica C, et al.: Randomized controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis. Lancet 1997, 350:550\u2013556.","journal-title":"Lancet"},{"key":"83_CR16","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1359\/jbmr.2001.16.5.925","volume":"16","author":"F Cosman","year":"2001","unstructured":"Cosman F, Nieves J, Woelfert L, et al.: Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001, 16:925\u2013931. This trial added hPTH 1-34 to estrogen and showed increase in bone mass and fracture reduction with combination therapy.","journal-title":"J Bone Miner Res"},{"key":"83_CR17","unstructured":"Ste-Marie LG, Scheele WH, Jasqui S, et al.: Effect of LY 333334 (recombinant human parathyroid hormone (1-34), rhPTH (1-34)) on bone density when given to postmenopausal women receiving hormone replacement therapy (HRT). Paper presented at the 84th Annual Meeting of the Endocrine Society. Denver, CO; June 20\u201323, 2001."},{"key":"83_CR18","first-page":"S15","volume":"18","author":"B Ettinger","year":"2003","unstructured":"Ettinger B, San Martin J, Crans GG, et al.: Response of markers of bone turnover and bone density to teriparatide in postmenopausal women previously treated with an antiresorptive drug. J Bone Miner Res 2003, 18(suppl):S15.","journal-title":"J Bone Miner Res"},{"key":"83_CR19","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, et al.: The effects of parathyroid hormone alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207\u20131215. Alendronate and PTH used together, shows impaired anabolic response to PTH.","journal-title":"N Engl J Med"},{"key":"83_CR20","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","volume":"349","author":"JS Finkelstein","year":"2003","unstructured":"Finkelstein JS, Hayes A, Hunzelman JL, et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216\u20131226. Study in men that shows the effect of alendronate added to PTH impairs the anabolic response to PTH.","journal-title":"N Engl J Med"},{"key":"83_CR21","first-page":"S135","volume":"17","author":"R Neer","year":"2002","unstructured":"Neer R, Hayes A, Rao A, et al.: Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic postmenopausal women. J Bone Miner Res 2002, 17(suppl):S135.","journal-title":"J Bone Miner Res"},{"key":"83_CR22","first-page":"2129","volume":"85","author":"RS Rittmaster","year":"2000","unstructured":"Rittmaster RS, Bolognese M, Ettinger MP, et al.: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000, 85:2129\u20132134. Parathyroid hormone for 1 year followed by alendronate has an additive effect on bone density response with continued increase in bone mass with alendronate therapy.","journal-title":"J Clin Endocrinol Metab"},{"key":"83_CR23","first-page":"620","volume":"82","author":"AB Hodsman","year":"1997","unstructured":"Hodsman AB, Fraher LJ, Watson PH, et al.: A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997, 82:620\u2013628.","journal-title":"J Clin Endocrinol Metab"},{"key":"83_CR24","first-page":"S40","volume":"18","author":"M McClung","year":"2003","unstructured":"McClung M, Miller P, Civitelli R, et al.: Differential effects of teriparatide and alendronate on markers of bone remodeling and areal and volumetric bone density in women with osteoporosis. J Bone Miner Res 2003, 18(suppl):S40.","journal-title":"J Bone Miner Res"},{"key":"83_CR25","first-page":"S179","volume":"6","author":"JJ Body","year":"2001","unstructured":"Body JJ, Gaich GA, Scheele WH, et al.: A randomized controlled clinical trial to compare the efficacy of LY333334 (recombinant human parathyroid hormone (1-34)) and alendronate sodium in postmenopausal women with osteoporosis. J Bone Miner Res 2001, 6(suppl):S179.","journal-title":"J Bone Miner Res"},{"key":"83_CR26","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","volume":"16","author":"DW Dempster","year":"2001","unstructured":"Dempster DW, Cosman F, Kurland ES, et al.: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846\u20131853. This study showed histologic effects of rhPTH 1-34 on trabecular bone, including increase in connectivity and cortical thickness.","journal-title":"J Bone Miner Res"},{"key":"83_CR27","first-page":"5","volume":"28","author":"L Hyldstrup","year":"2001","unstructured":"Hyldstrup L, Jorgensen JT, Gaich G, et al.: Assessment of effects of LY 333334 (recombinant human parathyroid hormone (1-34)) on cortical bone using digital x-ray radiogrammetry. Bone 2001, 28(suppl):5.","journal-title":"Bone"},{"key":"83_CR28","first-page":"5","volume":"28","author":"JR Zanchetta","year":"2001","unstructured":"Zanchetta JR, Bogado C, Ferretti JL, et al.: Effects of LY 333334 (recombinant parathyroid hormone (1-34)) on cortical bone strength indices as assessed by peripheral quantitative computed tomography. Bone 2001, 28(suppl):5.","journal-title":"Bone"},{"key":"83_CR29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S8756-3282(00)00316-1","volume":"27","author":"AB Hodsman","year":"2000","unstructured":"Hodsman AB: Histopomorphic evidence for increased bone turnover without change in cortical thickness or porosity after two years of cyclic hPTH (1-34) therapy and women with severe osteoporosis. Bone 2000, 27:311\u2013318.","journal-title":"Bone"},{"key":"83_CR30","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","volume":"102","author":"NE Lane","year":"1998","unstructured":"Lane NE, Sanchez S, Modin GW, et al.: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 1998, 102:1627\u20131633.","journal-title":"J Clin Invest"},{"key":"83_CR31","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1359\/jbmr.2000.15.5.944","volume":"15","author":"NE Lane","year":"2000","unstructured":"Lane NE, Sanchez S, Modin GW, et al.: Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000, 15:944\u2013951.","journal-title":"J Bone Miner Res"},{"key":"83_CR32","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S8756-3282(01)00433-1","volume":"28","author":"T. Mashiba","year":"2001","unstructured":"Mashiba T., Burr DB, Turner CH, et al.: Effects of a human parathyroid hormone (1-34), LY 333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 2001, 28:538\u2013547.","journal-title":"Bone"},{"key":"83_CR33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1359\/jbmr.2001.16.1.157","volume":"16","author":"DB Burr","year":"2001","unstructured":"Burr DB, Hirano T, Turner CH, et al.: Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of oophorectomized cynomolgus monkeys. JBMR 2001, 16:157\u2013165.","journal-title":"JBMR"},{"key":"83_CR34","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","volume":"11","author":"P Garnero","year":"1996","unstructured":"Garnero P, Hausherr E, Chapuy MC, et al.: Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996, 11:1531\u20131538.","journal-title":"J Bone Miner Res"},{"key":"83_CR35","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","volume":"30","author":"JL Vahle","year":"2002","unstructured":"Vahle JL, Sato M, Long GG, et al.: Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human data. Toxicol Pathol 2002, 30:312\u2013321.","journal-title":"Toxicol Pathol"},{"key":"83_CR36","unstructured":"Forteo teriparatide (rDNA origin) [packaging insert]. Indianapolis, IN: Eli Lilly and Company; 2002."},{"key":"83_CR37","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","volume":"285","author":"R Lindsay","year":"2001","unstructured":"Lindsay R, Silverman S, Cooper C, et al.: Risk of new vertebral fracture in the year following a fracture. JAMA 2001, 285:320\u2013323.","journal-title":"JAMA"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-004-0083-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-004-0083-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-004-0083-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:47:15Z","timestamp":1559422035000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-004-0083-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["83"],"URL":"https:\/\/doi.org\/10.1007\/s11926-004-0083-3","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}